Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced
immunological response and ultimately immune deficiency. Vacc-4x is a peptide-based HIV
immunotherapy and the primary objective is to strengthen the immune system's response to HIV
p24. By adding Lenalidomide, an immunomodulatory agent, as a supporting drug, it is
anticipated that the effect of Vacc-4x might be enhanced.